Gene · 5699
PSMB10: proteasome 20S subunit beta 10
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMB10: proteasome 20S subunit beta 10. Genes, record 5699. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5699
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P40306 | Proteasome subunit beta type-10 | 273 | 16 | Ensembl, GeneID, HGNC |
Source UniProt
Patents21
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59529 | P40306 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 7555 | P40306 | Espacenet |
| WO 2025190963 A1 | 2025-09-18 | 5 | P40306 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 7555 | P40306 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67901 | P40306 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170872 | P40306 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9062 | P40306 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 239964 | P40306 | Espacenet |
| EP 3403091 A1 | 2018-11-21 | 686 | P40306 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 239964 | P40306 | Espacenet |
1 to 10 of 21
See all 21 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| MARIZOMIB | CHEMBL371405 | 20S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,241
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,241
See all 1,241 trialsNIH grants1,299
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMB10 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 10 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 10 | 2025 |
| P30CA023108 | Cancer Center Support Grant | 6 | 2025 |
| R01AI143714 | Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials | 6 | 2025 |
| P50CA097190 | Head and Neck Cancer SPORE | 5 | 2025 |
| P20GM109036 | Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases | 4 | 2025 |
| R01AR041398 | Novel Molecular Biomarkers of Bone Microarchitecture | 4 | 2025 |
| T32DA017629 | Prevention and Methodology Training | 4 | 2025 |
| U19AG055373 | Trans-omics Integration of Multi-omics Studies for Osteoporosis | 4 | 2025 |
| P30CA016520 | Abramson Cancer Center Support Grant | 3 | 2025 |
1 to 10 of 1,299Source NIH's project files
See all 1,299 nih grantsPapers1,534
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MLN4924 suppresses kidney renal clear cell carcinoma progression through coordinated inhibition of Cullin1 neddylation and PSMB10-associated NF-κB inflammatory signaling. | Inflamm Res | 2026 | 42802181 | PubTator, text mining | PubMed |
| A Novel Dominantly Segregating PSMB10 Splice-Site Variant in Familial Autoinflammatory Disease with Immunoproteasome and Interferon-Related Dysregulation. | Genes (Basel) | 2026 | 42792891 | PubTator, text mining | PubMed |
| Type I and II Interferon Signalling Characterizes the Transcriptional Landscape of Sweet Syndrome. | Exp Dermatol | 2026 | 42410891 | PubTator, text mining | PubMed |
| From polyamine metabolism genes to immunoproteasome subunits: a transcriptome-based screening of candidate biomarkers in Crohn's disease. | Sci Rep | 2026 | 42401658 | PubTator, text mining | PubMed |
| Pan-cancer analysis identifies immunoproteasome as the predominant survival-associated component of antigen processing machinery. | Transl Oncol | 2026 | 42364494 | PubTator, text mining | PubMed |
| Functional characterization of EcPSMB10: Suppression of RGNNV replication via inhibiting autophagy in vitro. | Fish Shellfish Immunol | 2026 | 42229675 | PubTator, text mining | PubMed |
| Identification of Polyamine Metabolism-Related Biomarkers in Psoriasis: A Study Based on Transcriptomics and Single-Cell Sequencing. | Exp Dermatol | 2026 | 42223029 | PubTator, text mining | PubMed |
| NSCLC brain metastases exhibit reduced HLA-I antigen presentation machinery and immune evasion independent of IFNγ signaling defects. | Mol Cancer | 2026 | 42210261 | PubTator, text mining | PubMed |
| Novel de novo dominant PSMB10 variants in three patients with immune deficiency and liver disease. | J Hum Immun | 2026 | 42170594 | PubTator, text mining | PubMed |
| Monoallelic PSMB8 variants cause PRAAS with immunodeficiency through impaired immunoproteasome assembly. | Am J Hum Genet | 2026 | 42167218 | PubTator, text mining | PubMed |
1 to 10 of 1,534
See all 1,534 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5699
GET https://conductscience.org/api/genes/v1/5699/patents?page=2